Eli Lilly (LLY) Could Be 19% Undervalued After Novo Nordisk Lawsuit
Novo Nordisk’s lawsuit over obesity and diabetes drug advertising has pulled Eli Lilly (LLY) further into the spotlight and raised fresh questions about how this legal challenge could intersect with the stock’s recent strength.
See our latest analysis for Eli Lilly.
Against this backdrop, Eli Lilly’s share price has recently eased about 1% over 30 days after reaching record territory. Shorter term momentum remains positive with a 90 day share price return of 37.75% and a 1 year total shareholder return of 48.21%. Longer term holders have seen very large five year total shareholder returns as obesity and diabetes drugs, acquisitions in neuroscience and data partnerships such as the Billion Cell Atlas alliance keep the story in focus.
If you are weighing what other healthcare opportunities might benefit from similar trends in AI and drug development, it could be worth scanning a curated list of 40 healthcare AI stocks
Bulls argue Eli Lilly’s obesity and neuroscience engines justify a premium after the latest record highs, while bears point to legal risk and rich expectations. Which side looks closer to fair value when you crunch the numbers?
Most Popular Narrative: 19% Undervalued
The most followed valuation narrative on Eli Lilly pegs fair value at $1,477.03, which sits above the last close of $1,196.03 and frames the recent share price surge in a different light.
You are buying a business already growing at 25% annually, with its most important new drug not yet approved and not yet reflected in any revenue number, at a price that a conservative model says is 27 to 32% below fair value. The pricing headwinds are real, but they are happening to a company with manufacturing scale, regulatory depth, and a next-generation compound that has already beaten the highest analyst expectations in Phase 3. That is the story. Everything after this is just watching the trial readouts come in.
Curious what sits behind that fair value for Eli Lilly? Growth assumptions, margin expectations, and a future earnings multiple all have to line up. The narrative pulls these pieces together in a way current headlines do not.
Result: Fair Value of $1,477.03 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Eli Lilly’s narrative could shift quickly if pricing pressure on obesity drugs intensifies further or if legal outcomes around marketing practices become more restrictive.
Find out about the key risks to this Eli Lilly narrative.
Another View: What Eli Lilly’s P/E Is Signalling
While the user narrative leans on cash flows to argue Eli Lilly is undervalued, the current P/E of 42.2x tells a more cautious story. It sits above the US Pharmaceuticals industry at 14.9x, the peer average at 25.6x, and even above an estimated fair ratio of 39.5x. This points to higher valuation risk if expectations cool.
For investors weighing whether that premium is justified by Eli Lilly’s obesity and neuroscience pipeline or stretched by enthusiasm, See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Given the mix of optimism and concern around Eli Lilly, now is a good moment to review the underlying data yourself and stress test your stance. To size up both sides of the story, start by checking the 3 key rewards and 2 important warning signs.
Looking For More Investment Ideas Beyond Eli Lilly?
If Eli Lilly has sharpened your interest in healthcare and quality businesses, now is a good time to widen your watchlist with some targeted stock ideas.
- Spot potential bargains early by reviewing the screener containing 19 high quality undiscovered gems before they appear on everyone else's radar.
- Strengthen your core holdings with companies highlighted in the solid balance sheet and fundamentals stocks screener (49 results), where financial resilience is front and center.
- Reduce portfolio stress by focusing on the 79 resilient stocks with low risk scores, curated for stocks with lower risk scores that may suit steadier investors.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com